Lembas is an AI-powered bioactive discovery company pioneering the next generation of science-backed ingredients for functional foods and supplements. Our first solution GLP-1 Edge™, is a natural peptide that supports appetite regulation and metabolic health by enhancing the body’s own GLP-1 response.
GLP-1 Edge™ is food-grade, clinically validated, and easy to integrate into everyday products like bars, shakes, snacks, gummies, and supplements. It works with the body, not against it, making it an ideal companion for consumers looking to manage their weight naturally, safely, and sustainably.
At the core of Lembas is a proprietary AI platform that accelerates the discovery and design of targeted bioactive peptides. Backed by patent-pending university technology, Lembas is unlocking new bioactive ingredients across a broader range of health and wellbeing benefits. This is just the beginning. Stay tuned.
Founded in 2024, Lembas is backed by leading investors including Flora Ventures, Bluestein, Fresh Fund, Longevity Venture Partners, Maia Ventures, Siddhi Capital, Mandi Ventures, and SDH. Our team brings deep expertise in biotech, nutrition, AI, and consumer health, with leadership experience from companies like Mondelez, PepsiCo, IFF, Brightseed, and Shiru.
Backed by science. Designed for real life.
Company Details
- Employees
- 10
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.hellolembas.com
- Keywords
- Rotterdam.
Lembas Questions
Lembas's website is http://www.hellolembas.com
Lembas's LinkedIn profile is https://www.linkedin.com/company/hellolembas
Lembas has
10 employees.
View email and phone details for 10
employees at Lembas.
Lembas's industry is
Biotechnology Research
Lembas's top competitors are
Biotax,
Mandi Ventures,
Bluestein Ventures,
Gnomica Biotherapy,
Umbo,
Maia Ventures,
Fresh Fund,
Metabolize,
Flora Ventures,
Lembas.
Lembas's categories are Biotechnology Research
Lembas's founding year is 2024
